Tempus AI (TEM) said Wednesday its US Food and Drug Administration-approved next-generation sequencing test xT CDx for solid tumor profiling is now available nationwide.
Using a normal-matched approach, where a solid tumor and a normal patient sample are sequenced in parallel, xT CDx can more accurately detect cancer-driving somatic variants, the company said.
All orders for tumor + normal match tests, previously conducted through the company's xT assay, will transition to xT CDx without changing the current ordering workflow, it added.
The company's shares were up 8.9% in recent trading.
Price: 34.67, Change: +2.84, Percent Change: +8.91
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。